Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANIP ANI Pharmaceuticals	$62.00 -0.5%	$66.93	$52.50 ▼ $77.00	$1.35B	0.56	292,850 shs	418,019 shs
NUVL Nuvalent	$71.42 -3.0%	$71.41	$55.54 ▼ $113.51	$5.11B	1.42	487,025 shs	487,324 shs
OGN Organon & Co.	$8.43 -3.2%	$12.63	$8.05 ▼ $23.10	$2.19B	0.75	3.09 million shs	7.47 million shs
PTCT PTC Therapeutics	$46.39 +0.8%	$48.74	$28.72 ▼ $58.38	$3.68B	0.52	852,899 shs	1.08 million shs

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANIP ANI Pharmaceuticals	-0.48%	-11.77%	-8.98%	+3.89%	-7.93%
NUVL Nuvalent	-3.00%	+4.74%	+7.74%	-12.09%	+8.08%
OGN Organon & Co.	-3.01%	-7.87%	-24.50%	-42.65%	-59.76%
PTCT PTC Therapeutics	+0.83%	+28.18%	+7.93%	-5.19%	+46.34%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANIP ANI Pharmaceuticals	4.8544 of 5 stars	4.5	3.0	0.0	3.3	3.9	3.3	1.3
NUVL Nuvalent	2.6257 of 5 stars	3.5	2.0	0.0	0.0	3.5	3.3	0.0
OGN Organon & Co.	4.9123 of 5 stars	3.0	2.0	3.3	3.7	3.2	3.3	3.1
PTCT PTC Therapeutics	4.2528 of 5 stars	4.3	3.0	0.0	4.4	2.5	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANIP ANI Pharmaceuticals	3.00	Buy	$80.13	29.23% Upside
NUVL Nuvalent	2.90	Moderate Buy	$115.50	61.72% Upside
OGN Organon & Co.	2.00	Hold	$18.00	113.52% Upside
PTCT PTC Therapeutics	2.67	Moderate Buy	$61.92	33.48% Upside

Current Analyst Ratings Breakdown

Latest ANIP, NUVL, PTCT, and OGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/12/2025	ANIP ANI Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$86.00 ➝ $86.00
5/9/2025	PTCT PTC Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$55.00 ➝ $68.00
5/8/2025	PTCT PTC Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$56.00 ➝ $42.00
5/7/2025	PTCT PTC Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$57.00 ➝ $58.00
5/7/2025	PTCT PTC Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$70.00 ➝ $66.00
5/7/2025	PTCT PTC Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$113.00 ➝ $112.00
5/7/2025	PTCT PTC Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$75.00 ➝ $67.00
5/7/2025	PTCT PTC Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Sell ➝ Neutral	$50.00 ➝ $40.00
5/5/2025	OGN Organon & Co.	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$15.00 ➝ $10.00
5/2/2025	OGN Organon & Co.	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Inline
4/22/2025	PTCT PTC Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$65.00 ➝ $65.00

(Data available from 5/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANIP ANI Pharmaceuticals	$614.38M	2.20	$6.87 per share	9.03	$21.13 per share	2.93
NUVL Nuvalent	N/A	N/A	N/A	N/A	$10.94 per share	N/A
OGN Organon & Co.	$6.29B	0.35	$2.70 per share	3.12	($0.27) per share	-31.22
PTCT PTC Therapeutics	$1.77B	2.07	$2.23 per share	20.80	($10.85) per share	-4.28

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANIP ANI Pharmaceuticals	$18.78M	-$1.27	N/A	14.73	N/A	-1.28%	15.87%	6.88%	N/A
NUVL Nuvalent	-$126.22M	-$4.39	N/A	N/A	N/A	N/A	-28.63%	-27.15%	N/A
OGN Organon & Co.	$864M	$2.88	2.53	2.25	0.90	13.49%	431.62%	8.03%	N/A
PTCT PTC Therapeutics	-$626.60M	$6.51	N/A	N/A	N/A	-50.32%	N/A	-16.44%	N/A

Latest ANIP, NUVL, PTCT, and OGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/9/2025	Q1 2025	ANIP ANI Pharmaceuticals	$1.37	$1.70	+$0.33	$0.69	$179.75 million	$197.12 million
5/8/2025	Q1 2025	NUVL Nuvalent	-$1.14	-$1.18	-$0.04	-$1.18	N/A	N/A
5/6/2025	Q1 2025	PTCT PTC Therapeutics	$0.85	$10.04	+$9.19	N/A	$437.16 million	$1.18 billion
5/1/2025	Q1 2025	OGN Organon & Co.	$0.89	$1.02	+$0.13	$0.33	$1.53 billion	$1.51 billion
2/27/2025	Q4 2024	NUVL Nuvalent	-$1.03	-$1.05	-$0.02	-$1.05	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANIP ANI Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NUVL Nuvalent	N/A	N/A	N/A	N/A	N/A
OGN Organon & Co.	$0.08	0.95%	+25.99%	2.78%	N/A
PTCT PTC Therapeutics	N/A	N/A	N/A	N/A	N/A

Latest ANIP, NUVL, PTCT, and OGN Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/2/2025	OGN Organon & Co.	quarterly	$0.02	0.8%	5/12/2025	5/12/2025	6/12/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANIP ANI Pharmaceuticals	1.52	2.74	1.97
NUVL Nuvalent	N/A	23.07	23.07
OGN Organon & Co.	17.73	1.70	1.21
PTCT PTC Therapeutics	N/A	2.10	2.04

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANIP ANI Pharmaceuticals	76.05%
NUVL Nuvalent	97.26%
OGN Organon & Co.	77.43%
PTCT PTC Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
ANIP ANI Pharmaceuticals	11.10%
NUVL Nuvalent	12.52%
OGN Organon & Co.	1.96%
PTCT PTC Therapeutics	5.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANIP ANI Pharmaceuticals	600	21.77 million	18.36 million	Optionable
NUVL Nuvalent	40	71.60 million	62.16 million	Optionable
OGN Organon & Co.	10,000	259.96 million	253.93 million	Not Optionable
PTCT PTC Therapeutics	1,410	79.26 million	72.88 million	Optionable

ANIP, NUVL, PTCT, and OGN Headlines

Recent News About These Companies

Jacobs Levy Equity Management Inc. Sells 659,778 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT)

May 14 at 5:58 AM | marketbeat.com

Did PTC Therapeutics, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - PTCT

May 13 at 12:25 PM | accessnewswire.com

Shareholders that lost money on PTC Therapeutics, Inc. (PTCT) should contact Levi & Korsinsky about Securities Fraud Investigation - PTCT

May 13 at 10:15 AM | accessnewswire.com

PTC Therapeutics, Inc. (PTCT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

May 13 at 10:00 AM | accessnewswire.com

Northern Trust Corp Grows Position in PTC Therapeutics, Inc. (NASDAQ:PTCT)

May 13 at 4:17 AM | marketbeat.com

Investors Who Lost Money on PTC Therapeutics, Inc. Should Contact Levi & Korsinsky About an Ongoing Investigation - PTCT

May 12 at 5:30 PM | accessnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT

May 12 at 5:07 PM | prnewswire.com

Shareholders that lost money on PTC Therapeutics, Inc. (PTCT) should contact Levi & Korsinsky about Securities Fraud Investigation - PTCT

May 12 at 10:30 AM | accessnewswire.com

Bronstein, Gewirtz & Grossman, LLC Is Investigating PTC Therapeutics, Inc. (PTCT) And Encourages Investors to Connect

May 12 at 10:00 AM | accessnewswire.com

Brevan Howard Capital Management LP Takes $551,000 Position in PTC Therapeutics, Inc. (NASDAQ:PTCT)

May 12 at 4:45 AM | marketbeat.com

PTC Therapeutics (NASDAQ:PTCT) Upgraded to "Buy" at Bank of America

May 12 at 1:44 AM | americanbankingnews.com

PTC Therapeutics, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details- PTCT

May 11 at 11:00 AM | accessnewswire.com

Bronstein, Gewirtz & Grossman, LLC Is Investigating PTC Therapeutics, Inc. (PTCT) And Encourages Stockholders to Connect

May 11 at 10:00 AM | accessnewswire.com

PTC Therapeutics (NASDAQ:PTCT) Rating Increased to Buy at Bank of America

May 11 at 8:51 AM | marketbeat.com

Leerink Partnrs Has Bullish Forecast for PTCT Q1 Earnings

May 11 at 8:11 AM | marketbeat.com

William Blair Lifts Earnings Estimates for PTC Therapeutics

May 11 at 8:11 AM | marketbeat.com

PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Purchased by Cubist Systematic Strategies LLC

May 11 at 6:23 AM | marketbeat.com

Cantor Fitzgerald Issues Positive Estimate for PTCT Earnings

May 11 at 2:39 AM | americanbankingnews.com

William Blair Issues Optimistic Forecast for PTCT Earnings

May 11 at 1:09 AM | americanbankingnews.com

Shareholder Rights Advocates at Levi & Korsinsky Investigate PTC Therapeutics, Inc. (PTCT) Regarding Possible Securities Fraud Violations

May 10, 2025 | accessnewswire.com

PTC Therapeutics, Inc. (PTCT): Among Billionaire David E. Shaw’s Small-Cap Stock Picks with Huge Upside Potential

May 10, 2025 | insidermonkey.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANIP, NUVL, PTCT, and OGN Company Descriptions

ANI Pharmaceuticals NASDAQ:ANIP

$62.00 -0.30 (-0.48%)

As of 05/13/2025 04:00 PM Eastern

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

Nuvalent NASDAQ:NUVL

$71.42 -2.21 (-3.00%)

As of 05/13/2025 04:00 PM Eastern

Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Organon & Co. NYSE:OGN

$8.43 -0.28 (-3.21%)

Closing price 05/13/2025 03:59 PM Eastern

Extended Trading

$8.46 +0.04 (+0.42%)

As of 08:24 AM Eastern

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

PTC Therapeutics NASDAQ:PTCT

$46.39 +0.38 (+0.83%)

Closing price 05/13/2025 04:00 PM Eastern

Extended Trading

$46.98 +0.59 (+1.28%)

As of 08:00 AM Eastern

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time